nVNS — Non-Invasive Vagus Nerve Stimulation

Evidence-supportedB/CgradePlausibility · PlausibleElectroceuticals / Bioelectronic Medicine

Evidence-supported · Evidence-supported

Episodic cluster headache (FDA 2017) and migraine (FDA 2018) — gammaCore.

Off-label · Insufficient-evidence

Broad longevity / HRV / anti-aging / biohacking wellness use.

Real vagal neuromodulation with FDA clearances for specific headache indications; widely sold off-label for HRV / longevity / biohacking, where the evidence is frontier.

Origin & lineage

Bioelectronic medicine; electroCore gammaCore (cleared late 2010s).

Claimed mechanism

Transcutaneous cervical or auricular vagal stimulation → afferent neuromodulation of brainstem / autonomic circuits + the cholinergic anti-inflammatory pathway.

Plausibility

Plausible — real neuromodulation with a defined afferent vagal pathway.

Evidence — grade B/C

B for the cleared headache indications; C for broad wellness / HRV / longevity off-label.

Market

Makers: electroCore (gammaCore, Rx); auricular taVNS: Nurosym / Parasym, Pulsetto, Truvaga.
Models: gammaCore; Nurosym; Pulsetto; Truvaga.
Price: Auricular taVNS ~$200–700.

Kernel — keep vs set aside

Keep — real substrate

Real vagal neuromodulation; the cleared headache indications are solid.

Set aside — claim

Broad 'longevity / HRV / anti-aging / biohacking' claims are off-label frontier, not established.

Regulatory status by jurisdiction

Registration or clearance is a market-access fact, never proof of efficacy.

US — FDA	Cleared 510(k) — gammaCore: acute migraine (K173442, decision 2018-01-23); cluster headache prevention + acute cluster (K182369, decision 2018-11-27); episodic cluster acute first cleared 2017. Rx.
EU — MDR	CE marked.
Russia	Not found.
China — NMPA	Not found.
Australia — TGA	Not found.

Sources

FDA 510(k) records verified via openFDA (K173442 gammaCore-S, decision 2018-01-23, acute migraine; K182369 gammaCore Sapphire, decision 2018-11-27, cluster headache). Pivotal RCT: PREVA (Gaul et al., Cephalalgia 2016) — PMC4853813 (full text confirmed). PRESTO (acute migraine RCT, ClinicalTrials NCT02686034) is a further pivotal trial; primary-source URL not yet locked, omitted rather than fabricated.